What is your recommended approach for managing patients who do not respond to ruxolitinib therapy for vitiligo?

Featuring Benjamin Lockshin, MD | EVP of Strategic InitiativesDirector of the Clinical Trials CenterAssistant ProfessorUS Dermatology PartnersGeorgetown UniversityRockville, MD | Published July 01, 2024